{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:37:07Z","timestamp":1792705027906,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":45,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100337","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T14:34:53Z","timestamp":1613918093000},"page":"100337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma"],"prefix":"10.1016","volume":"27","author":[{"given":"Alessandro","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Dalia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctarc.2021.100337_bib0001","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100337_bib0002","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5604\/16652681.1226927","article-title":"Intrahepatic, perihilar and distal cholangiocarcinoma: management and outcomes","volume":"16","author":"Waseem","year":"2017","journal-title":"Ann Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2021.100337_bib0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.ctarc.2021.100337_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","author":"Banales","year":"2020","journal-title":"Nat. Rev Gastroenterol Hepatol."},{"key":"10.1016\/j.ctarc.2021.100337_bib0005","first-page":"1","article-title":"Recent advances of immunotherapy for biliary tract cancer","author":"Rizzo","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol"},{"issue":"9935","key":"10.1016\/j.ctarc.2021.100337_bib0006","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2021.100337_bib0007","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2021.100337_bib0008","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1200\/EDBK_160831","article-title":"Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling","volume":"35","author":"Bridgewater","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100337_bib0009","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/liv.13517","article-title":"Risk estimation for biliary tract cancer: development and validation of a prognostic score","volume":"37","author":"Schweitzer","year":"2017","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100337_bib0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat. Rev. Gastroenterol Hepatol."},{"issue":"4","key":"10.1016\/j.ctarc.2021.100337_bib0011","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/ags3.12266","article-title":"Essential updates to the surgical treatment of biliary tract cancer","volume":"3","author":"Matsukuma","year":"2019","journal-title":"Ann Gastroenterol. Surg"},{"key":"10.1016\/j.ctarc.2021.100337_bib0012","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg."},{"issue":"4","key":"10.1016\/j.ctarc.2021.100337_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/SLA.0000000000002385","article-title":"Surgical management of gallbladder cancer: simple versus extended cholecystectomy and the role of adjuvant therapy","volume":"266","author":"Kasumova","year":"2017","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100337_bib0014","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100337_bib0015","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a Randomized Phase III Study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100337_bib0016","first-page":"1","article-title":"BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care","author":"Rizzo","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100337_bib0017","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctarc.2021.100337_bib0018","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100337_bib0019","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann. Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100337_bib0020","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","article-title":"Systemic therapies for intrahepatic cholangiocarcinoma","volume":"72","author":"Kelley","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100337_bib0021","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/cancers13030558","article-title":"PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer","volume":"13","author":"Rizzo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2021.100337_bib0022","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2016.08.013","article-title":"Molecular characteristics of biliary tract cancer","volume":"107","author":"Sohal","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100337_bib0023","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol."},{"key":"10.1016\/j.ctarc.2021.100337_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103119","article-title":"Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma","volume":"156","author":"Lamberti","year":"2020","journal-title":"Crit Rev Oncol. Hematol"},{"key":"10.1016\/j.ctarc.2021.100337_bib0025","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/cancers12082308","article-title":"Evolution of the experimental models of cholangiocarcinoma","volume":"12","author":"Massa","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100337_bib0026","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.3390\/cancers12082126","article-title":"Genomic database analysis of uterine leiomyosarcoma mutational profile","volume":"12","author":"Astolfi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100337_bib0027","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New Horizons for Precision Medicine in Biliary Tract Cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100337_bib0028","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11864-020-00767-3","article-title":"New treatment options for advanced biliary tract cancer","volume":"21","author":"Mizrahi","year":"2020","journal-title":"Curr Treat Options Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2021.100337_bib0029","doi-asserted-by":"crossref","first-page":"44","DOI":"10.21037\/cco.2019.08.14","article-title":"Systemic therapy for gallbladder cancer","volume":"8","author":"Javle","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100337_bib0030","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.3390\/cancers12082190","article-title":"Molecular and immunological characterization of biliary tract cancers: a paradigm shift towards a personalized medicine","volume":"12","author":"Malenica","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2021.100337_bib0031","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"J Gastrointest Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100337_bib0032","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2017.03.026","article-title":"Emerging molecular therapeutic targets for cholangiocarcinoma","volume":"67","author":"Rizvi","year":"2017","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100337_bib0033","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctarc.2021.100337_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101998","article-title":"Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation","volume":"86","author":"Athauda","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100337_bib0035","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100337_bib0036","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820948047","article-title":"Immunotherapy in biliary tract cancer: worthy of a second look","volume":"27","author":"Ricci","year":"2020","journal-title":"Cancer Control"},{"issue":"24","key":"10.1016\/j.ctarc.2021.100337_bib0037","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100337_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001042","article-title":"The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?","volume":"5","author":"Ricci","year":"2020","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100337_bib0039","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3390\/cancers12051237","article-title":"Biliary Tract Cancer: current Medical Treatment Strategies","volume":"12","author":"Oneda","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100337_bib0040","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jjco\/hyy082","article-title":"New developments in systemic therapy for advanced biliary tract cancer","volume":"48","author":"Morizane","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100337_bib0041","doi-asserted-by":"crossref","DOI":"10.1177\/1073274817729241","article-title":"Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma","volume":"24","author":"Chun","year":"2017","journal-title":"Cancer Control"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100337_bib0042","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/13543784.2018.1512581","article-title":"Novel targeted treatment options for advanced cholangiocarcinoma","volume":"27","author":"Mahipal","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"10.1016\/j.ctarc.2021.100337_bib0043","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100337_bib0044","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3390\/cancers12082039","article-title":"Targeted therapies in advanced biliary tract cancer: an evolving paradigm","volume":"12","author":"Chakrabarti","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100337_bib0045","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.3390\/cancers12092599","article-title":"Recent progress in the systemic treatment of advanced\/metastatic cholangiocarcinoma","volume":"12","author":"Fostea","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2021.100337_bib0046","first-page":"1","article-title":"The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs","author":"Sipra","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ctarc.2021.100337_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100337_bib0048","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100337_bib0049","doi-asserted-by":"crossref","first-page":"441","DOI":"10.21873\/cgp.20203","article-title":"Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives","volume":"17","author":"Rizzo","year":"2020","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.ctarc.2021.100337_bib0050","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920953293","article-title":"FGFR inhibitors in cholangiocarcinoma: what's now and what's next?","volume":"12","author":"Saborowski","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100337_bib0051","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctarc.2021.100337_bib0052","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pharmthera.2017.05.013","article-title":"Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach","volume":"179","author":"Presta","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ctarc.2021.100337_bib0053","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctarc.2021.100337_bib0054","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.03.015","article-title":"Targeting the fibroblast growth factor receptor family in cancer","volume":"46","author":"Hallinan","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100337_bib0055","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100337_bib0056","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3390\/cancers12061449","article-title":"Current strategies and novel therapeutic approaches for metastatic urothelial carcinoma","volume":"12","author":"Mollica","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2021.100337_bib0057","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.breast.2017.10.014","article-title":"Targeting FGFR pathway in breast cancer","volume":"37","author":"Perez-Garcia","year":"2018","journal-title":"Breast"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100337_bib0058","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/13543784.2017.1353599","article-title":"Nintedanib in ovarian cancer","volume":"26","author":"Khalique","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100337_bib0059","doi-asserted-by":"crossref","first-page":"789","DOI":"10.21037\/jgo.2016.08.12","article-title":"The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?","volume":"7","author":"Rizvi","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ctarc.2021.100337_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2019.06.003","article-title":"FGFR2 genomic aberrations: achilles heel in the management of advanced cholangiocarcinoma","volume":"78","author":"Mahipal","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100337_bib0061","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/MOG.0000000000000162","article-title":"Genetics of Opisthorchis viverrini-related cholangiocarcinoma","volume":"31","author":"Jusakul","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.ctarc.2021.100337_bib0062","doi-asserted-by":"crossref","DOI":"10.21037\/jgo.2017.05.04","article-title":"Current biologics for treatment of biliary tract cancers","author":"Zhao","year":"2017","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100337_bib0063","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bpg.2015.02.002","article-title":"Pathogenesis of cholangiocarcinoma: from genetics to signalling pathways","volume":"29","author":"Kongpetch","year":"2015","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100337_bib0064","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100337_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100337_bib0066","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100337_bib0067","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PLoS Genet"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100337_bib0068","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100337_bib0069","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2021.100337_bib0070","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100337_bib0071","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S1470-2045(20)30152-2","article-title":"FGFR inhibitors for advanced cholangiocarcinoma","volume":"21","author":"Yang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ctarc.2021.100337_bib0072","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/bjc.2017.119","article-title":"The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma","volume":"116","author":"Shroff","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100337_bib0073","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12885-020-07365-4","article-title":"Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results","volume":"20","author":"Ueno","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100337_bib0074","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100337_bib0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00280-012-1982-z","article-title":"A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors","volume":"71","author":"Plummer","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100337_bib0076","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.21873\/anticanres.14282","article-title":"Second-line treatment in advanced biliary tract cancer: today and tomorrow","volume":"40","author":"Rizzo","year":"2020","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100337_bib0077","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100337_bib0078","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2021.100337_bib0079","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.108","article-title":"FOENIX-CCA2: a phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements","volume":"38","author":"Goyal","year":"2020","journal-title":"J. Clin Oncol."},{"key":"10.1016\/j.ctarc.2021.100337_bib0080","first-page":"1","article-title":"Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives","author":"Rizzo","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100337_bib0081","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-Competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctarc.2021.100337_bib0082","article-title":"Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma","author":"Merz","year":"2020","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100337_bib0083","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100337_bib0084","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-17-0057","article-title":"Gatekeeper mutations and intratumoral heterogeneity in FGFR2-translocated cholangiocarcinoma","volume":"7","author":"Smyth","year":"2017","journal-title":"Cancer Discov"},{"issue":"4 Pt B","key":"10.1016\/j.ctarc.2021.100337_bib0085","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.bbadis.2017.08.002","article-title":"The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma","volume":"1864","author":"Macias","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100337_bib0086","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/2326-6066.CIR-18-0595","article-title":"The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity","volume":"7","author":"Palakurthi","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctarc.2021.100337_bib0087","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-19-LB-C12","article-title":"Derazantinib (DZB): a dual FGFR\/CSF1R- inhibitor active in PDX-models of urothelial cancer","volume":"18","author":"McSheehy","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"29","key":"10.1016\/j.ctarc.2021.100337_bib0088","doi-asserted-by":"crossref","first-page":"48436","DOI":"10.18632\/oncotarget.17061","article-title":"Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:20:23Z","timestamp":1762842023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221000368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":88,"alternative-id":["S2468294221000368"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100337","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100337"}}